This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Ensign Group's Inorganic Growth Impresses, Debt Level Hurts
by Zacks Equity Research
Ensign Group's (ENSG) top line rises on inorganic and organic growth. Its financial health also impresses. However high level of costs and debts bother.
Molina Healthcare's Top Line Grows on Membership, Debts Hurt
by Zacks Equity Research
Molina Healthcare's (MOH) top line benefits from inorganic growth and membership. However, rising level of debt and expenses hurt margins.
WellCare Health Partners Mission Health to Improve Offerings
by Zacks Equity Research
WellCare Health Plans, Inc's (WCG) subsidiary, Wellcare of North Carolina recently entered into an agreement with Mission Health to provide better Medicaid and Medicare services in North Carolina.
Centene (CNC) Poised to Grow on Buyouts, High Debt Bothers
by Zacks Equity Research
Centene's (CNC) accretive acquisitions backed by solid financials add to its top line. However, high debt and rising expenses hurt margins.
Amedisys (AMED) Up 3.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Amedisys (AMED) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Chemed (CHE) is a Suitable Growth Pick for Now
by Zacks Equity Research
Banking on favorable Net Margin and ROE, Chemed (CHE) stands out as one of the most suitable growth stocks.
IDEXX Laboratories (IDXX), Great Growth Pick: Here's Why
by Zacks Equity Research
Banking on a number of favorable metrics, IDEXX Laboratories (IDXX) stands out as one of the most suitable growth stock.
Is Amedisys (AMED) a Great Value Stock for Your Portfolio?
by Zacks Equity Research
Banking on a number of favorable metrics, Amedisys (AMED) stands out as one of the most suitable value stock.
Here's Why Masimo (MASI) is a Suitable Value Pick for Now
by Zacks Equity Research
Masimo (MASI) seems to be a solid value pick with favorable P/E ratio and P/FCF ratio compared with its broader industry.
Here's Why Investors Should Buy Amedisys (AMED) Right Now
by Zacks Equity Research
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.
Tabula Rasa Healthcare (TRHC) Catches Eye: Stock Up 9.5%
by Zacks Equity Research
Tabula Rasa Healthcare, Inc. (TRHC) shares rose around 10% in the last trading session.
Aetna's (AET) $1 Billion Notes Due 2047 Rated By A.M Best
by Zacks Equity Research
Rating Giant A.M Bests assigned a Long-Term Issue Credit Rating of "bbb" to Aetna's (AET) $1 billion, 3.875% senior notes due to mature on Aug 15, 2047.
Envision Healthcare Hurt by High Debt, Increasing Expenses
by Zacks Equity Research
Envision Healthcare's (EVHC) increasing debt and expenses continue to hurt. Further guidance cut by the company is concerning.
Amedisys (AMED) Earnings & Revenues Miss Estimates in Q2
by Zacks Equity Research
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business in Q2.
Community Health Sells 2 Texas Units, Streamlines Business
by Zacks Equity Research
Community Health Systems, Inc.'s (CYH) subsidiaries have sold their ownership interest in two Texas hospitals and their associated assets to subsidiaries of HCA Healthcare.
Amedisys (AMED) Prospects Impressive Amid Tough Competition
by Zacks Equity Research
On Jun 5, we issued an updated research report on leading molecular diagnostic company, Amedisys, Inc. (AMED).
Why Is Amedisys (AMED) Up 4% Since the Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Beats on Q1 Earnings, Revenues Meet Mark
by Zacks Equity Research
Amedisys Inc. (AMED) reported adjusted earnings from continuing operations of 47 cents per share in the first quarter of 2017, up 42.4% year over year.
Healthcare Q1 Earnings Slated on May 2: AET, HCA & More
by Zacks Equity Research
The healthcare sector has been in the limelight since the change of power at the White House.
Amedisys (AMED) Poised on Strong Home Health, Risks Remain
by Zacks Equity Research
On Apr 04, we issued an updated research report on renowned home health and hospice services provider, Amedisys Inc. (AMED).
Amedisys to Buy East Tennessee to Expand in Personal Care
by Zacks Equity Research
Amedisys Inc. (AMED) recently signed a definitive agreement to buy substantially all of the assets of a Knoxville, TN-based personal care provider, East Tennessee Personal Care Service.
Amedisys Stock Up on Solid Earnings, Reimbursement Woes Stay
by Zacks Equity Research
On Mar 02, we issued an updated research report on renowned home health and hospice services provider Amedisys Inc. (AMED).
Tenet Healthcare (THC) to Divest Operations to Amedisys
by Zacks Equity Research
Tenet Healthcare Corporation (THC) recently announced that it has inked a deal with Amedisys, Inc. (AMED) to divest its Home Health and Hospice operations in Arizona, Illinois, Massachusetts and Texas to the latter
Amedisys (AMED) Catches Eye: Stock Gains 6.2% in Session
by Zacks Equity Research
Amedisys, Inc. (AMED) moved big last session, as its shares rose over 6% on the day.
Amedisys Buys 6 Home Health, Hospice Care Centers from Tenet
by Zacks Equity Research
Amedisys Inc. (AMED), a household name in home health and hospice services space, recently signed an exclusive agreement with Tenet Healthcare Corporation (THC).